A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00369941

First Posted: August 30, 2006

Last Update Posted: March 21, 2017

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by (Responsible Party):

Merck Sharp & Dohme Corp.

Results First Submitted: September 18, 2009

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment
Condition:	HIV Infections
Interventions:	Drug: MK-0518 Drug: Comparator: efavirenz Drug: Comparator: Truvada Drug: Comparator: Placebo to MK-0518 Drug: Comparator: Placebo to efavirenz

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Primary therapy period: 14-Sep-2006 to 06-May-2009 Multicenter (67) in the United States (18) and Ex-US (49)

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

Primary therapy period: 14-Sep-2006 to 06-May-2009

Multicenter (67) in the United States (18) and Ex-US (49)

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

Description

MK-0518 400 mg b.i.d.

MK-0518 400 mg, which can be taken by mouth (PO) twice a day (b.i.d.) without regard to food, and placebo to efavirenz, which will be taken PO at bedtime (q.h.s.) on an empty stomach preferably at bedtime. All participants will take one tablet of TRUVADA® (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) with food, daily with the morning dose of MK-0518. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.

Efavirenz 600 mg q.h.s.

Efavirenz 600 mg, which will be taken by mouth (PO) at bedtime (q.h.s.) on an empty stomach preferably at bedtime, and placebo to MK-0518, which will be taken PO twice a day (b.i.d.) without regard to food. All participants will take one tablet of TRUVADA® with food, daily with the morning dose of placebo. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.

Participant Flow: Overall Study

	MK-0518 400 mg b.i.d.	Efavirenz 600 mg q.h.s.
STARTED	282	284
Treated	281	282
COMPLETED	210	184
NOT COMPLETED	72	100
Never Treated	1	2
Adverse Event	14	28
Lack of Efficacy	6	10
Lost to Follow-up	12	22
Protocol Violation	5	3
Withdrawal by Subject	5	18
Pregnancy	4	2
Completed, Did Not Enter Extension	5	6
Moved	11	5
Treatment with Prohibited Medication	3	1
Employment Interfered with Study Visits	1	0
Study Site Terminated	2	0
Miscellaneous	3	3

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
MK-0518 400 mg b.i.d.	MK-0518 400 mg, which can be taken by mouth (PO) twice a day (b.i.d.) without regard to food, and placebo to efavirenz, which will be taken PO at bedtime (q.h.s.) on an empty stomach preferably at bedtime. All participants will take one tablet of TRUVADA® (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) with food, daily with the morning dose of MK-0518. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
Efavirenz 600 mg q.h.s.	Efavirenz 600 mg, which will be taken by mouth (PO) at bedtime (q.h.s.) on an empty stomach preferably at bedtime, and placebo to MK-0518, which will be taken PO twice a day (b.i.d.) without regard to food. All participants will take one tablet of TRUVADA® with food, daily with the morning dose of placebo. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
Total	Total of all reporting groups

Baseline Measures

	MK-0518 400 mg b.i.d.	Efavirenz 600 mg q.h.s.	Total
Overall Participants Analyzed [Units: Participants]	281	282	563

Age [Units: Years] Mean (Full Range)	38 (19 to 67)	37 (19 to 71)	37 (19 to 71)

Sex: Female, Male [Units: Participants] Count of Participants
Female	54 19.2%	51 18.1%	105 18.7%
Male	227 80.8%	231 81.9%	458 81.3%

Race/Ethnicity, Customized [Units: Participants]
White	116	123	239
Black	33	23	56
Asian	36	32	68
Hispanic	60	67	127
Others	36	37	73

Cluster of Differentiation 4 (CD4) Cell Count [Units: Cells/mm^3] Mean (Full Range)	219 (1 to 620)	217 (4 to 807)	218 (1 to 807)

Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) [Units: Copies/mL] Geometric Mean (Full Range)	103205 (400 to 750000)	106215 (4410 to 750000)	104702 (400 to 750000)

Outcome Measures

Show All Outcome Measures

1. Primary:

Number of Participants Who Achieved Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) <50 Copies/mL at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 1

2. Primary:

Number of Participants With Clinical Adverse Experiences (CAEs) at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 2

3. Primary:

Number of Participants With Serious CAEs at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 3

4. Primary:

Number of Participants With Drug-related CAEs at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 4

5. Primary:

Number of Participants With Serious Drug-related CAEs at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 5

6. Primary:

Number of Participants That Died by Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 6

7. Primary:

Number of Participants That Discontinued With CAEs at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 7

8. Primary:

Number of Participants That Discontinued With Serious CAEs at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 8

9. Primary:

Number of Participants That Discontinued With Drug-related CAEs at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 9

10. Primary:

Number of Participants That Discontinued With Serious Drug-related CAEs at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 10

11. Primary:

Number of Participants With Laboratory Adverse Experiences (LAEs) at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 11

12. Primary:

Number of Participants With Serious LAEs at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 12

13. Primary:

Number of Participants With Drug-related LAEs at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 13

14. Primary:

Number of Participants With Serious Drug-related LAEs at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 14

15. Primary:

Number of Participants Discontinued With LAEs at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 15

16. Primary:

Number of Participants Discontinued With Drug-related LAEs at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 16

17. Secondary:

Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 48 [ Time Frame: 48 Weeks ]

Show Outcome Measure 17

18. Secondary:

Change From Baseline in Cluster of Differentiation Antigen 4 (CD4) Cell Count at Week 48 [ Time Frame: Baseline and Week 48 ]

Show Outcome Measure 18

19. Secondary:

Number of Participants Who Achieved HIV RNA <50 Copies/mL at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 19

20. Secondary:

Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 20

21. Secondary:

Change From Baseline in CD4 Cell Count at Week 96 [ Time Frame: Baseline and Week 96 ]

Show Outcome Measure 21

22. Secondary:

Number of Participants Who Achieved HIV RNA <50 Copies/mL at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 22

23. Secondary:

Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 23

24. Secondary:

Change From Baseline in CD4 Cell Count at Week 156 [ Time Frame: Baseline and Week 156 ]

Show Outcome Measure 24

25. Secondary:

Number of Participants Who Achieved HIV RNA <50 Copies/mL at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 25

26. Secondary:

Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 26

27. Secondary:

Change From Baseline in CD4 Cell Count at Week 240 [ Time Frame: Baseline and Week 240 ]

Show Outcome Measure 27

28. Secondary:

Number of Participants With Nervous System Symptoms Assessed by Review of Accumulated Safety Data up to Week 8 [ Time Frame: 8 Weeks ]

Show Outcome Measure 28

29. Secondary:

Number of Participants With CAEs at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 29

30. Secondary:

Number of Participants With CAEs at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 30

31. Secondary:

Number of Participants With CAEs at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 31

32. Secondary:

Number of Participants With Serious CAEs at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 32

33. Secondary:

Number of Participants With Serious CAEs at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 33

34. Secondary:

Number of Participants With Serious CAEs at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 34

35. Secondary:

Number of Participants With Drug-related CAEs at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 35

36. Secondary:

Number of Participants With Drug-related CAEs at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 36

37. Secondary:

Number of Participants With Drug-related CAEs at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 37

38. Secondary:

Number of Participants With Serious Drug-related CAEs at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 38

39. Secondary:

Number of Participants With Serious Drug-related CAEs at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 39

40. Secondary:

Number of Participants With Serious Drug-related CAEs at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 40

41. Secondary:

Number of Participants That Died by Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 41

42. Secondary:

Number of Participants That Died by Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 42

43. Secondary:

Number of Participants That Died by Week 240 [ Time Frame: 240 Weeks ]

Hide Outcome Measure 43

Measure Type	Secondary
Measure Title	Number of Participants That Died by Week 240
Measure Description	All participant deaths in the span of 240 weeks on study were recorded.
Time Frame	240 Weeks

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All participants who took study medication were included in the analysis.

Reporting Groups

Description

MK-0518 400 mg b.i.d.

Efavirenz 600 mg q.h.s.

Measured Values

	MK-0518 400 mg b.i.d.	Efavirenz 600 mg q.h.s.
Participants Analyzed [Units: Participants]	281	282
Number of Participants That Died by Week 240 [Units: Participants]
Died	5	5
Did Not Die	276	277

No statistical analysis provided for Number of Participants That Died by Week 240

44. Secondary:

Number of Participants That Discontinued With CAEs at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 44

45. Secondary:

Number of Participants That Discontinued With CAEs at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 45

46. Secondary:

Number of Participants That Discontinued With CAEs at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 46

47. Secondary:

Number of Participants That Discontinued With Drug-related CAEs at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 47

48. Secondary:

Number of Participants That Discontinued With Drug-related CAEs at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 48

49. Secondary:

Number of Participants That Discontinued With Drug-related CAEs at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 49

50. Secondary:

Number of Participants That Discontinued With Serious CAEs at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 50

51. Secondary:

Number of Participants That Discontinued With Serious CAEs at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 51

52. Secondary:

Number of Participants That Discontinued With Serious CAEs at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 52

53. Secondary:

Number of Participants That Discontinued With Serious Drug-related CAEs at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 53

54. Secondary:

Number of Participants That Discontinued With Serious Drug-related CAEs at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 54

55. Secondary:

Number of Participants That Discontinued With Serious Drug-related CAEs at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 55

56. Secondary:

Number of Participants With LAEs at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 56

57. Secondary:

Number of Participants With LAEs at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 57

58. Secondary:

Number of Participants With LAEs at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 58

59. Secondary:

Number of Participants With Drug-related LAEs at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 59

60. Secondary:

Number of Participants With Drug-related LAEs at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 60

61. Secondary:

Number of Participants With Drug-related LAEs at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 61

62. Secondary:

Number of Participants With Serious LAEs at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 62

63. Secondary:

Number of Participants With Serious LAEs at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 63

64. Secondary:

Number of Participants With Serious LAEs at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 64

65. Secondary:

Number of Participants With Serious Drug-related LAEs at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 65

66. Secondary:

Number of Participants With Serious Drug-related LAEs at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 66

67. Secondary:

Number of Participants With Serious Drug-related LAEs at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 67

68. Secondary:

Number of Participants Discontinued With LAEs at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 68

69. Secondary:

Number of Participants Discontinued With LAEs at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 69

70. Secondary:

Number of Participants Discontinued With LAEs at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 70

71. Secondary:

Number of Participants Discontinued With Drug-related LAEs at Week 96 [ Time Frame: 96 Weeks ]

Show Outcome Measure 71

72. Secondary:

Number of Participants Discontinued With Drug-related LAEs at Week 156 [ Time Frame: 156 Weeks ]

Show Outcome Measure 72

73. Secondary:

Number of Participants Discontinued With Drug-related LAEs at Week 240 [ Time Frame: 240 Weeks ]

Show Outcome Measure 73

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.

Results Point of Contact:

Name/Title: Senior Vice President, Global Clinical Development
Organization: Merck Sharp & Dohme Corp
phone: 1-800-672-6372
e-mail: ClinicalTrialsDisclosure@merck.com

Publications of Results:

Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ, Barnard RJ, Miller MD, DiNubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009 Sep 5;374(9692):796-806. doi: 10.1016/S0140-6736(09)60918-1. Epub 2009 Aug 3. Erratum in: Lancet. 2009 Dec 19-2010 Jan 1;374(9707):2054. Lancet. 2009 Sep 5;374(9692):786.

DeJesus E, Rockstroh JK, Lennox JL, Saag MS, Lazzarin A, Zhao J, Wan H, Rodgers AJ, Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P; STARTMRK Investigators. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. HIV Clin Trials. 2012 Jul-Aug;13(4):228-32. doi: 10.1310/hct1304-228. Erratum in: HIV Clin Trials. 2012 Sep-Oct;13(5):preceding 233.

Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, Walker ML, Xu X, Zhao J, Teppler H, Dinubile MJ, Rodgers AJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK Investigators. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011 Oct;53(8):807-16. doi: 10.1093/cid/cir510.

Rockstroh J, Teppler H, Zhao J, Sklar P, Harvey C, Strohmaier K, Leavitt R, Nguyen BY. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med. 2012 Feb;13(2):127-31. doi: 10.1111/j.1468-1293.2011.00933.x. Epub 2011 May 22.

Rockstroh JK, Teppler H, Zhao J, Sklar P, Miller MD, Harvey CM, Strohmaier KM, Leavitt RY, Nguyen BY. Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. AIDS. 2011 Jul 17;25(11):1365-9. doi: 10.1097/QAD.0b013e328348065a.

Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA, Miller MD, Chen J, Kemp R, Xu W, Fromtling RA, Vacca JP, Young SD, Rowley M, Lower MW, Gottesdiener KM, Hazuda DJ. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci. 2011 Mar;1222:83-9. doi: 10.1111/j.1749-6632.2011.05972.x. Review.

Teppler H, Brown DD, Leavitt RY, Sklar P, Wan H, Xu X, Lievano F, Lehman HP, Mast TC, Nguyen BY. Long-term safety from the raltegravir clinical development program. Curr HIV Res. 2011 Jan;9(1):40-53.

Lennox JL, Dejesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, Zhao J, Wan H, Gilbert CL, Teppler H, Rodgers AJ, Barnard RJ, Miller MD, Dinubile MJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK Investigators. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr. 2010 Sep;55(1):39-48. doi: 10.1097/QAI.0b013e3181da1287. Erratum in: J Acquir Immune Defic Syndr. 2011 Dec 1;58(4):e120. Dosage error in article text.

Responsible Party:	Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:	NCT00369941 History of Changes
Other Study ID Numbers:	0518-021 MK-0518-021 ( Other Identifier: Merck ) 2006_519 ( Other Identifier: Merck Registration ID )
First Submitted:	August 29, 2006
First Posted:	August 30, 2006
Results First Submitted:	September 18, 2009
Results First Posted:	May 11, 2010
Last Update Posted:	March 21, 2017

To Top